MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Radial PCI
The advantages and limitations of 4- to 5-F guide catheters.
By Tejas Patel, MD, DM, FACC, FSCAI, FESC, and Samir B. Pancholy, MD, FACP, FACC, FSCAI
The Fine Points of Radial Hemostasis Management
Incorporating a patent hemostasis technique can maximize radial artery patency.
By Samir B. Pancholy, MD, FACP, FACC, FSCAI
Ask the Experts: Uptake of radial access in the United States: A glass half full?
With James Nolan, MBChB, FRCP, MD; Samir B. Pancholy, MD, FACP, FACC, FSCAI; Tejas Patel, MD, DM, FACC, FSCAI, FESC; and Sunil V. Rao, MD
REVERE Trial Compares Effect of Vascular Entry Sites on Radiation Exposure
August 21, 2015—Samir B. Pancholy MD, et al conducted the randomized noninferiority REVERE trial on radiation exposure during cardiac catheterization comparing femoral access (FA) with left radial access (LRA) and right radial access (RRA). The investigators published their findings in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2015;8:1189–1196).
PROPHET II Studies Prevention of Radial Artery Occlusion After Transradial Catheterization
October 4, 2016—The PROPHET II randomized trial sought to evaluate whether prophylactic ipsilateral ulnar artery compression during radial artery hemostasis could reduce the risk of radial artery occlusion (RAO), which is a structural complication of transradial access.
The Radial Shift
By Ted E. Feldman, MD, FESC, FACC, FSCAI
Optimal Access/Reliable Closure
By Ted E. Feldman, MD, MSCAI, FACC, FESC
Corindus Vascular Robotics' CorPath System Cleared for Radial Access PCI
October 6, 2015—Corindus Vascular Robotics, Inc. announced that the US Food and Drug Administration has given 510(k) clearance for the company’s robotic-assisted CorPath system to be used during percutaneous coronary interventions (PCIs) performed via radial access. The company noted that the 510(k) clearance was based on results of a clinical trial composed of 30 patients and demonstrated 100% device and clinical success. The trial was conducted at Spectrum Health in Grand Rapids, Michigan, and St.
Bioresorbables Plus Access & Closure
